United States was the largest of 10x Genomics, Inc.’s 5 reported lines in fiscal 2025, at $346.51M — 54% of $642.82M.
| Geography | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| United States | $284.99M | $360.09M | $334.32M | $346.51M | |||||
| Europe, Middle East & Africa | $117.07M | $142.28M | $159.76M | $161.72M | |||||
| North America | — | — | — | — | |||||
| Asia-Pacific (Excluding China) | $41.21M | $52.29M | $45.96M | $52.07M | |||||
| China | $64.36M | $50.97M | $57.30M | $70.26M | |||||
| Asia-Pacific | — | — | — | — | |||||
| Asia Pacific | — | — | — | — | |||||
| Americas (Excluding United States) | $8.79M | $13.10M | $13.45M | $12.26M | |||||
| North America (Excluding United States) | — | — | — | — | |||||
| Total | $516.41M | $618.73M | $610.79M | $642.82M |
In fiscal 2025, which ended December 31, 2025, the 5 regions 10x Genomics, Inc. reported in this breakdown added up to $642.82M. That was up 5.2% from $610.79M in fiscal 2024. United States was the largest region, at $346.51M or 53.9% of the total, followed by Europe, Middle East & Africa ($161.72M, 25.2%) and China ($70.26M, 10.9%). Together, the two largest regions made up 79.1% of this total.
Compared with fiscal 2024, China grew the fastest, rising 22.6% to $70.26M. Every sizeable region reported in both years grew. Over fiscal 2022 to 2025, revenue across these regions went from $516.41M to $642.82M, a compound annual growth rate of 7.6%. United States' share of the total fell from 55.2% to 53.9% over the same years.
The table also keeps 4 regions that 10x Genomics, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 4 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2017 to 2025, as reported in 10x Genomics, Inc.'s annual filings.
License & Royalty Revenue was the largest of 10x Genomics, Inc.’s 4 reported lines in fiscal 2025, at $46.14M — 34% of $135.64M.
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Chromium | $58.55M | — | — | — | |||||
| Single Cell | — | $47.87M | $35.21M | $22.67M | |||||
| Consumables | — | — | — | — | |||||
| Spatial | $13.84M | $75.61M | $57.50M | $34.11M | |||||
| Instruments | — | — | — | — | |||||
| Instuments | — | — | — | — | |||||
| License & Royalty Revenue | — | — | $321.00K | $46.14M | |||||
| Services | $8.43M | $15.70M | $24.32M | $32.73M | |||||
| Service | — | — | — | — | |||||
| Total | $80.82M | $139.17M | $117.35M | $135.64M |
In fiscal 2025, which ended December 31, 2025, the 4 revenue lines 10x Genomics, Inc. reported in this breakdown added up to $135.64M. That is less than the $642.82M in its breakdown by region, so these revenue lines do not account for all of its revenue that year. License & Royalty Revenue was the largest revenue line, at $46.14M or 34.0% of the total, followed by Spatial ($34.11M, 25.1%) and Services ($32.73M, 24.1%). Together, the two largest revenue lines made up 59.2% of this total.
Compared with fiscal 2024, License & Royalty Revenue grew the fastest, rising 14,272.3% to $46.14M. Spatial fell the most, down 40.7% to $34.11M.
Single Cell (fiscal 2023) and License & Royalty Revenue (fiscal 2024) were first reported as separate revenue lines during this period. The table also keeps 5 revenue lines that 10x Genomics, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 5 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2017 to 2025, as reported in 10x Genomics, Inc.'s annual filings.
10x Genomics, Inc. (TXG) breaks its revenue down by region and revenue line. In fiscal 2025, its largest region was United States, with $346.51M or 53.9% of the total, followed by Europe, Middle East & Africa at $161.72M (25.2%).
United States was 10x Genomics, Inc.'s largest region in fiscal 2025, with $346.51M in revenue, 53.9% of the $642.82M reported across its 5 regions.
License & Royalty Revenue was 10x Genomics, Inc.'s largest revenue line in fiscal 2025, with $46.14M in revenue, 34.0% of the $135.64M reported across its 4 revenue lines.
Of the 10x Genomics, Inc. regions reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, China grew the fastest, rising 22.6% from $57.30M to $70.26M.
Every figure is taken from 10x Genomics, Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by region covers fiscal 2017 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.